経口投与の未分化ヘパリンとキャリア剤は,深静脈血栓症の治療効果があります
M D Gonze1, K Salartash, W C Sternbergh
1Department of Surgery, The Ochsner Medical Institutions, New Orleans, LA, USA.
Circulation
|June 7, 2000
まとめ
経口投与のヘパリンとSNACを併用して,ネズミの深静脈血栓症 (DVT) を効果的に治療し,低分子量ヘパリンと同様の結果を示しました. この新しい経口製剤は,DVT治療の有望な代替品を提供します.
科学分野:
- 薬理学 薬理学とは
- トロンボシス研究研究
- 薬物の配送システムです.
背景:
- 口服ヘパリン (OHEP) は生物学的利用性が低く,治療効果が限られている.
- ナトリウムN-(8[2-ヒドロキシベンゾイル]アミノ) カプリラート (SNAC) は,胃腸経路での薬剤投与のための吸収強化剤です.
- OHEPとSNAC (OHEP/SNAC) の組み合わせは,深静脈血栓症 (DVT) の治療のために調査されました.
研究 の 目的:
- DVTのラットモデルにおけるOHEP/SNACの有効性を評価する.
- OHEP/SNACの有効性を既存のヘパリン製剤と対照群と比較する.
主な方法:
- 深い静脈栓塞は,スプラグ・ダウリー・ラットで誘発された.
- 動物は7日間,様々な薬剤で治療された:未治療対照群,皮膚下ヘパリン (SC HEP),SNACのみ,OHEPのみ,低分子量ヘパリン (LMWH),OHEP/SNAC.
- 活性化された部分血栓形成時間 (aPTT) と抗X因子 (anti-Xa) レベルを測定した.
主要な成果:
- OHEP/SNACとLMWHは,残留DVTの発生率を著しく減少させた (10%対100%対照群,P<0.001).
- OHEP/SNACとLMWHは,対照群と比較して,凝固重量の有意な減少を示した.
- OHEP/SNACは,他のグループと比較して,投与後のaPTTと抗Xa濃度の有意に高い値を示した.
結論:
- OHEP/SNACは,ネズミのモデルで,DVTの治療に有意な効果を示した.
- OHEPとキャリアSNACの組み合わせは,LMWHに匹敵する治療効果を達成しました.
- この研究は,SNACが,DVTの管理において,経口ヘパリン投与のキャリアとしての可能性を強調しています.
関連する概念動画
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Venous Thrombosis I: Introduction
822
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
822
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
469
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
469
Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Venous Thrombosis IV: Nursing Management
415
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
415


